RARRES2 and metabolic syndrome: In recent studies, chemerin was also found to positively correlate with systemic inflammation biomakers (i.e. CRP, WBC count), insulin resistance, dyslipidemia and hepatic disorders in incident and maintenance HD patients34,35.